ODE III dermatology office director
Executive Summary
Susan Walker will head FDA's Office of Drug Evaluation III Division of Dermatology & Dental Products within the Center for Drug Evaluation & Research, replacing Jonathan Wilkin who retired in September. Walker's wide-ranging agency experience includes service as director of the Division of Dietary Supplement programs in the Office of Nutritional Products, Labeling & Dietary Supplements in CFSAN and deputy director on detail to the Division of General, Restorative & Neurological Devices in the Office of Device Evaluation in CDRH. She has also previously worked for the dermatology office as medical officer and later as medical team leader...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.